Table 1 Anthracycline chemotherapy - Low and Moderate Risk

Timeline	Baseline	C1D1	C2D1	C3D1	3M	C4D1	C5D1	6M	C6D1	9M	12M/3 M	24M/12M
											post	post
											treatment	treatment
Procedures											treatment	u cumont
Screening/Eligibility	v		ı		1	1		1		1	<u> </u>	1
Informed Consent	X											
Screening/Eligibility	X											
Enrolment form	X											
1. Medical History 2. HFA-ICOS Risk Assessment 3. Baseline Cancer Details	X											
4. Oncological Treatment												
Demographics												
Vital signs and BMI	X		X			X		X		X		
Medications (CV & Other	er)			•								
CV Medications	X		X			X		X		X		
Concomitant Medications	X		X			X		Х		X		
Cardiac Biomarkers (cTn/NP)	X		X			X			X		Х	
Lipid Profile	X		X			X			X		X	X
Urea & Electrolytes	Х		X			X			X		X	Х
Biobank				ı	ı	l		I.		I.		•
Bloods for Biobank	X		X			X			X	X	X	X
Baseline Measurements/Follow-Up Measurements												
ECG	X											
TTE +/- Stress Echocardiography	Х					X						Х
Cardiac MRI**	X					X						X
CT scan of the chest (Cardiac, breast)****	Х											
Cardiac Toxicity & Can	cer Related	Events			1	_		1		T		
Cardiac Event Form and Phone Interview					X			X		X	X	Х
ePRO Quality of Life Surveys ***(QLQ-30; QLQ-BR45; EQ-5D-	х				Х			Х		X	Х	х
5L; Perceived Stress Scale; Self-Evaluation)												

- **Cardiac MRI only in subset of patients if required based on Echocardiography findings/Cardiology opinion
- ***surveys include EORTC QLQ-C30, EORTC QLQ BR 45, EQ-5D-5L, Perceived Stress Scale PSS-10, State Trait Anxiety Inventory (STAI)
- **** Will be done if oncologically indicated and assessed by cardiology team for calcification index

^{*}saliva only collected in high risk patients who will be wearing smart sensors

Table 2 Anthracycline based chemotherapy - High and Very High Risk

Timeline	Baseline	C1D1	C2D1	3M	C3D1	C4D1	C5D1	6M	C6D1	9M	12M/3 M post treatment	24M/12M post treatment
Screening/Eligibility												
Informed Consent	X											
Screening/Eligibility	X											
Enrolment form	X											
1. Medical History 2. HFA-ICOS Risk Assessment 3. Baseline Cancer Details	X											
4. Oncological T												
Demographics						l .	l .	·		ı	<u>'</u>	
Weight, BP and BMI	X		X			X		X		X		
Medications (CV & Other	er)					I.	I.	l		I.		
CV Medication Review	X		X			X		X		X		
Concomitant Medications	Х		Х			X		х		X		
Cardiac Biomarkers (cTn/NP)	X	Х	Х		X	Х	Х		Х		X	X
Lipid Profile	X		X			X			X		X	X
Urea & Electrolytes	X		X			X			X		X	X
Biobank												
Bloods for Biobank	X		X		X	X			X	X	X	X
saliva* for Biobank	X		X		X	X			X	X	X	
Baseline Measurements/	Follow-Up	Measure	ements									
ECG	X											
TTE +/- Stress Echocardiography	X		X			X			X		Х	Х
Cardiac MRI**	X		X			X			X		X	X
CT scan of the chest (Cardiac, breast)****	X											
Cardiac Toxicity & Can	cer Related	Events	T	,		T	T		T	T	T	
Cardiac Event Form and Phone Interview			Х			X			X	Х	X	Х
ePRO Quality of Life Surveys ***(QLQ-30; QLQ-BR45; EQ-5D- 5L; Perceived Stress Scale; Self-Evaluation)	x ollected in h			X				X		X	X	X

^{*}saliva only collected in high risk patients who will be wearing smart sensors

^{**}Cardiac MRI only in subset of patients if required based on Echocardiography findings/Cardiology opinion

^{***}surveys include EORTC QLQ-C30, EORTC QLQ BR 45, EQ-5D-5L, Perceived Stress Scale PSS-10, State Trait Anxiety Inventory (STAI)

^{****} Will be done if oncologically indicated and assessed by cardiology team for calcification index

Table 3 Her2 Targeted Therapy –Low and Moderate Risk

Timeline	Baseline	3M	6M	9M	12M	24M/12M post treatment
Screening/Eligibility	•	•	•			
Informed Consent	X					
Screening/Eligibility	X					
Enrolment form	X					
 Medical History HFA-ICOS Risk Assessment Baseline Cancer Details Oncological Treatment 	X					
Demographics						
Weight BP and BMI	X	X	X	X	X	X
Medications (CV & Other)						
CV Medication Review	X	X	X	X	X	X
Other Medications	X	X	X	X	X	X
Cardiac Biomarkers (cTn/NP)	X	х	х	X	X	X
Lipid Profile	X	X	X	X	X	X
Urea & Electrolytes	X	X	X	X	X	X
Biobank						
Bloods for Biobank	X	X	X	X	X	X
Baseline Measurements/Follow-Up Measurement	ts					
TTE +/- Stress Echocardiography	X	X	X	X	X	X
Cardiac MRI**	X	X	X	X	X	X
ECG	X					X
CT scan of the chest (Cardiac, breast)****	X					
Cardiac Toxicity & Cancer Related Events	•					
Cardiac Event Form and Phone Interview		X	X	X	X	X
ePRO Quality of Life Surveys *** (QLQ-30; QLQ-BR45; EQ-5D-5L; Perceived Stress Scale; Self-Evaluation)	Х	Х	Х	X	X	Х

^{*}saliva only collected in high risk patients who will be wearing smart sensors

^{**}Cardiac MRI only in subset of patients if required based on Echocardiography findings/Cardiology opinion

^{***}surveys include EORTC QLQ-C30, EORTC QLQ BR 45, EQ-5D-5L, Perceived Stress Scale PSS-10, State Trait Anxiety Inventory (STAI)

^{****} Will be done if oncologically indicated and assessed by cardiology team for calcification index

Table 4 Her2 Targeted Therapy – High Risk and Very High Risk

Timeline	Baseline	3M	6M	9M	12M	15M/3M post treatment	24M/12M post treatment
Procedures							
Screening/Eligibility		1			I	1	
Informed Consent	X						
Screening/Eligibility	X						
Enrollment form	X						
 Medical History HFA-ICOS Risk Assessment Baseline Cancer Details Oncological Treatment 	X						
Demographics							
Weight BP and BMI	X	X	X	X	X		X
Medications (CV & Other)							
CV Medication Review	X	X	X	X	X		X
Other Medications	X	X	X	X	X		X
Cardiac Biomarkers (cTn/NP)	X	Х	X	X	X	X	X
Lipid Profile	X	X	X	X	X	X	X
Urea & Electrolytes	X	X	X	X	X	X	X
Biobank							
Bloods for biobank	X	X	X	X	X	X	X
Saliva for Biobank	X	X	X	X	X	X	X
Baseline Measurements/Follow-Up Me	asurement	S			ı		
TTE +/- Stress Echocardiography	X	X	X	X	X	X	X
Cardiac MRI**	X	X	X	X	X	X	X
ECG	X						
CT scan of the chest (Cardiac, breast)****	X						
Cardiac Toxicity & Cancer Related Ev	ents						
Cardiac Event Form and Phone Interview		X	X	X	X		х
ePRO Quality of Life Surveys *** (QLQ-30; QLQ-BR45; EQ-5D-5L; Perceived Stress Scale; Self- Evaluation) **solive only collected in high risk petion	Х	X	X	X	х		Х

^{*}saliva only collected in high risk patients who will be wearing smart sensors

^{**}Cardiac MRI only in subset of patients if required based on Echocardiography findings/Cardiology opinion

^{***}surveys include EORTC QLQ-C30, EORTC QLQ BR 45, EQ-5D-5L, Perceived Stress Scale PSS-10, State Trait Anxiety Inventory (STAI)

^{****} Will be done if oncologically indicated and assessed by cardiology team for calcification index